A Phase 1b/2 Study of the Combination of Pepinemab and Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Latest Information Update: 03 Jul 2024
At a glance
- Drugs Pembrolizumab (Primary) ; Pepinemab (Primary)
- Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms KEYNOTE B84
- Sponsors Vaccinex
- 04 Jun 2024 Results assessing correlative and spatial biomarker analysis presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 26 Feb 2024 Planned End Date changed from 4 Sep 2023 to 31 Dec 2024.
- 26 Feb 2024 Planned primary completion date changed from 4 Sep 2023 to 31 Dec 2024.